-
5 days ago | 
ophthalmologytimes.com | Sheryl Stevenson
As the 19th Annual Controversies in Modern Eye Care (CIME) conference approaches on May 4 at the Sheraton Grand Los Angeles, California, cochair Neda Shamie, MD, sat down with Ophthalmology Times and Optometry Times® to discuss this year’s agenda. Alongside cochairs Robert Maloney, MD, and Arjan Hura, MD, of the Maloney-Shamie-Hura Vision Institute, Shamie will lead discussions on the latest advancements and controversies in eye care, focusing on the collaborative care model.
-
2 weeks ago | 
optometrytimes.com | Sheryl Stevenson |Jordana Joy
Orasis Pharmaceuticals announced that its novel corrective eye drop for the treatment of presbyopia in adults (Qlosi; pilocarpine hydrochloride ophthalmic solution 0.4%) is available to prescribe in the US.¹ The topical ophthalmic solution is preservative-free, packaged in single-use vials, and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.¹ Patients can enjoy the flexibility of using a single drop per eye for improved near vision for a...
-
2 weeks ago | 
ophthalmologytimes.com | Sheryl Stevenson
Orasis Pharmaceuticals announced that its novel corrective eye drop for the treatment of presbyopia in adults (Qlosi; pilocarpine hydrochloride ophthalmic solution 0.4%) is available to prescribe in the US.¹ The topical ophthalmic solution is preservative-free, packaged in single-use vials, and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.¹ Patients can enjoy the flexibility of using a single drop per eye for improved near vision for a...
-
3 weeks ago | 
optometrytimes.com | Neda Shamie |Sheryl Stevenson
To learn more about or to register for the 19th Annual Controversies in Modern Eye Care meeting, click here. Neda Shamie, MD, sat down with the Eye Care Network to highlight the key themes of the upcoming 19th Annual Controversies in Modern Eye Care meeting, which she co-chairs alongside Robert Maloney, MD, and Arjan Hura, MD, of the Maloney-Shamie-Hura Vision Institute.
-
3 weeks ago | 
ophthalmologytimes.com | Neda Shamie |Sheryl Stevenson
To learn more about or to register for the 19th Annual Controversies in Modern Eye Care meeting, click here. Neda Shamie, MD, sat down with the Eye Care Network to highlight the key themes of the upcoming 19th Annual Controversies in Modern Eye Care meeting, which she co-chairs alongside Robert Maloney, MD, and Arjan Hura, MD, of the Maloney-Shamie-Hura Vision Institute.
-
4 weeks ago | 
ophthalmologytimes.com | Kenneth Beckman |Sheryl Stevenson
Author(s):,Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and laser-assisted techniques. Kenneth Beckman, MD, discussed the latest advancements in epithelium-on (epi-on) corneal crosslinking, highlighting new accelerated protocols and innovative approaches to overcoming previous limitations in a presentation at the World Cornea Congress IX, held March 20 to 22, 2025, in Washington, DC.
-
4 weeks ago | 
ophthalmologytimes.com | Sheryl Stevenson
As part of the celebration of Ophthalmology Times’ 50th Anniversary, George O. Waring IV, MD, FACS, medical director of the Waring Vision Institute in Mount Pleasant, South Carolina, highlights 5 decades of advancements in cornea, cataract, and refractive surgery, emphasizing the evolving concept of “vision for a lifetime.” This approach ensures that vision correction procedures are available for every stage of ocular maturity, integrating corneal and lens-based refractive strategies.
-
1 month ago | 
ophthalmologytimes.com | Mona A. Kaleem |Sheryl Stevenson
Mona Kaleem, MD, highlighted findings from the Gemini study, which evaluated the Omni surgical system for up to 3 years in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, and pigmentary glaucoma, at the 2025 American Glaucoma Society (AGS) Annual Meeting, held February 26 to March 2 in Washington, DC. The procedure combined 360-degree canaloplasty with 180-degree goniotomy to enhance aqueous outflow.
-
1 month ago | 
ophthalmologytimes.com | Martin Friedlander |Anat Loewenstein |Mohammad Rafieetary |Sheryl Stevenson
The approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) as the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel) marks a significant milestone for patients with the progressive retinal disease.1 The implantable device uses encapsulated cell therapy (ECT) technology to continuously deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina, helping to slow disease progression.The approval was based on the results from...
-
1 month ago | 
ophthalmologytimes.com | Sheryl Stevenson
The Australian Society of Ophthalmologists (ASO) announces the appointment of Katrina Ronne as its first woman chief executive officer (CEO) in the organization’s 43-year history,1 a milestone in the society’s leadership that coincides with International Women’s Day on March 8. Ronne, who has served as ASO’s general manager of policy and strategy for much of the past decade, assumes the role following significant contributions to the society’s advocacy efforts.
